Off-Target Effects with Matt Gline

4 Episodes

Reverse

Episode 4: Matt speaks with Philip Ross, one of the most experienced and successful bankers in healthcare, about the M&A landscape and his decision to join Jefferies last year

2025-06-3026:46

Philip Ross talks about the outlook for M&A in our industry, and describes the pharma revenue growth demands that will be driving it. He discusses what qualities make targets attractive, and how the industry has changed over time during the course of his career. Plus, what attracted him to Jefferies.

Episode 3: Matt speaks with STAT News' Adam Feuerstein about the dynamics of biotech journalism and how it compares to other industries

2025-05-0837:13

Adam shares his background of previously covering the tech industry, and compares and contrasts it to covering biotech. He describes his philosophy of writing for investors, and how the business of journalism does and doesn't affect the types of stories he writes.

Episode 2: Matt speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector

2025-04-1033:50

One of the largest and most successful biotech investors, Dr. Aghazadeh is asked about key current events like turnover at FDA, tariffs, China, and whether he thinks biotech has a structural problem regarding how companies 'innovate' today and the different market strategies of investors.

Episode 1: From SF Healthcare Week, Matt interviews Brad Loncar about M&A and China's potential impact on it

2025-02-1732:06

For the first episode of the new video podcast, Matt turns the tables on Brad Loncar and interviews him about his experiences and knowledge of investing in China biotech over the years. They discuss the rise of China biotech and how it might or might not be impacting M&A in the sector.

#box-pro-ellipsis-175897885241116{-webkit-line-clamp:2;}Off-Target Effects with Matt Gline